These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38804196)

  • 21. [Bone and Nutrition. Nutrition care of renal osteodystrophy].
    Tanaka S; Ito M
    Clin Calcium; 2015 Jul; 25(7):1057-62. PubMed ID: 26119320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnosis and management of osteoporosis in chronic kidney disease stages 4 to 5D: a call for a shift from nihilism to pragmatism.
    Evenepoel P; Cunningham J; Ferrari S; Haarhaus M; Javaid MK; Lafage-Proust MH; Prieto-Alhambra D; Torres PU; Cannata-Andia J; ; ;
    Osteoporos Int; 2021 Dec; 32(12):2397-2405. PubMed ID: 34129059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone biomarkers in de novo renal transplant recipients.
    Evenepoel P; Cavalier E; D'Haese PC
    Clin Chim Acta; 2020 Feb; 501():179-185. PubMed ID: 31734147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone turnover markers: understanding their value in clinical trials and clinical practice.
    Civitelli R; Armamento-Villareal R; Napoli N
    Osteoporos Int; 2009 Jun; 20(6):843-51. PubMed ID: 19190842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone kidney interactions.
    Nickolas TL; Jamal SA
    Rev Endocr Metab Disord; 2015 Jun; 16(2):157-63. PubMed ID: 26156535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical utility of bone turnover markers in the management of common metabolic bone diseases in adults.
    Glendenning P; Chubb SAP; Vasikaran S
    Clin Chim Acta; 2018 Jun; 481():161-170. PubMed ID: 29544749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic kidney disease and fragility fracture.
    Kazama JJ
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):46-52. PubMed ID: 28012057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The potential use of antisclerostin therapy in chronic kidney disease-mineral and bone disorder.
    Costa AG; Bilezikian JP; Lewiecki EM
    Curr Opin Nephrol Hypertens; 2015 Jul; 24(4):324-9. PubMed ID: 26050118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical utility of bone marker measurements in osteoporosis.
    Wheater G; Elshahaly M; Tuck SP; Datta HK; van Laar JM
    J Transl Med; 2013 Aug; 11():201. PubMed ID: 23984630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mineral and bone disorder after kidney transplantation: a single-center cohort study.
    Sun L; Wang Z; Zheng M; Hang Z; Liu J; Gao X; Gui Z; Feng D; Zhang D; Han Q; Fei S; Chen H; Tao J; Han Z; Ju X; Gu M; Tan R
    Ren Fail; 2023 Dec; 45(1):2210231. PubMed ID: 37183797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis.
    Lorentzon M; Branco J; Brandi ML; Bruyère O; Chapurlat R; Cooper C; Cortet B; Diez-Perez A; Ferrari S; Gasparik A; Herrmann M; Jorgensen NR; Kanis J; Kaufman JM; Laslop A; Locquet M; Matijevic R; McCloskey E; Minisola S; Pikner R; Reginster JY; Rizzoli R; Szulc P; Vlaskovska M; Cavalier E
    Adv Ther; 2019 Oct; 36(10):2811-2824. PubMed ID: 31440982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Updates on Lifestyle-Related Diseases and Bone Metabolism. CKD-related osteoporosis].
    Yamada S; Inaba M
    Clin Calcium; 2014 Nov; 24(11):1605-13. PubMed ID: 25355144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone Fragility Fractures in CKD Patients.
    Pimentel A; Ureña-Torres P; Bover J; Luis Fernandez-Martín J; Cohen-Solal M
    Calcif Tissue Int; 2021 Apr; 108(4):539-550. PubMed ID: 33219822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in Bone Histomorphometry after Kidney Transplantation.
    Keronen S; Martola L; Finne P; Burton IS; Kröger H; Honkanen E
    Clin J Am Soc Nephrol; 2019 Jun; 14(6):894-903. PubMed ID: 31088851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biochemical Markers of Bone Turnover and their Role in Osteoporosis Diagnosis: A Narrative Review.
    Khashayar P; Meybodi HA; Amoabediny G; Larijani B
    Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(2):79-89. PubMed ID: 26246012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osteoporosis and adynamic bone in chronic kidney disease.
    Cannata-Andía JB; Rodriguez García M; Gómez Alonso C
    J Nephrol; 2013; 26(1):73-80. PubMed ID: 23023723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of potential biomarkers for osteoporosis using LC-MS/MS metabolomic methods.
    Wang J; Yan D; Zhao A; Hou X; Zheng X; Chen P; Bao Y; Jia W; Hu C; Zhang ZL; Jia W
    Osteoporos Int; 2019 Jul; 30(7):1491-1499. PubMed ID: 30778642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current concepts and management strategies in chronic kidney disease-mineral and bone disorder.
    Chauhan V; Kelepouris E; Chauhan N; Vaid M
    South Med J; 2012 Sep; 105(9):479-85. PubMed ID: 22948328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Chronic Kidney Disease Mineral and Bone Disorder on Jaw and Alveolar Bone Metabolism: A Narrative Review.
    Kanjevac T; Bijelic B; Brajkovic D; Vasovic M; Stolic R
    Oral Health Prev Dent; 2018; 16(1):79-85. PubMed ID: 29459907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of biochemical markers in the management of osteoporosis.
    Henriksen K; Christiansen C; Karsdal MA
    Climacteric; 2015; 18 Suppl 2():10-8. PubMed ID: 26507704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.